The Problem You Are Facing
Your pharma started an AI initiative twelve to eighteen months ago. There was a steering committee. There was a roadmap. There was a vendor demo that landed well in the executive room. There was a pilot scoped to a single function, a single use case, a single therapeutic area.
The pilot ran. The demo deck became a longer demo deck. The internal stakeholders wrote case studies for their own performance reviews. The vendor invoice went up.
Then nothing moved.
The pilot did not graduate to production. The use case did not extend to a second function. The board still asks for an "AI strategy update" every quarter and the slide that comes back is structurally the same as the slide from a year ago.
You already know this is happening. Your CIO knows. Your CFO is starting to ask uncomfortable questions about the year-over-year AI spend. And every time someone proposes "what if we just hired a Chief AI Officer," the room gets quieter because nobody believes a title fixes this.
You are not unusual. McKinsey reports that nearly two-thirds of organizations are still stuck in pilot mode. Boston Consulting Group finds that sixty percent of companies are getting hardly any material value from their AI investments. Gartner forecasts that thirty percent of generative AI projects will be abandoned entirely after the POC phase. In pharma manufacturing specifically, ninety-five percent of AI pilots fail to deliver measurable business value.
The pattern is so consistent that it has a name. Pilot purgatory. And the reason pharma sits inside it more painfully than most industries is that the typical reasons pilots get stuck are amplified by pharma's regulatory environment, data complexity, and operating model.
Here are the three real reasons your pilot is stuck. None of them are "your team is not technical enough."
Reason 1: You Picked the Wrong Starting Use Case
The single most common mistake I see across pharma AI initiatives is that the first use case was selected for visibility, not for leverage.
Drug discovery AI. Brand-level personalization. KOL graph analysis. Generative content for medical affairs. All of them look exciting in a board deck. All of them have one thing in common: the value chain from the AI output to a measurable business outcome is long, indirect, and politically contested.
When the pilot delivers a result, three different functions disagree about whether the result is meaningful, three different stakeholders disagree about what should happen next, and the steering committee defers to "let's pilot it for another quarter." A use case with long value attribution distance is structurally designed to live in PowerPoint forever.
The use cases that get out of pilot purgatory share three properties. The output is consumed inside a single function. The cost or revenue change is directly measurable within sixty days. And the operational owner of the function has full authority to operationalize the AI output without external sign-off.
Pharmacovigilance case processing. Field force pre-call briefing. MLR pre-screening. Adverse event triage. Doctor engagement at the long tail. KOL preparation for MSLs. Cross-functional decision routing. These are the use cases that move out of pilot because their value chain is short and their organizational ownership is clear.
You probably did not start with one of these. Most pharma AI programs do not. That is the first reason your pilot is stuck.
Reason 2: You Scoped a Demo, Not a Deployment
The second reason is that the pilot was scoped to prove the model could produce a plausible output, not to prove the model could operate inside your production environment under your governance constraints.
This is the difference between a POC and an MVP. A POC shows that the technology can do the task on a curated dataset under ideal conditions. An MVP is the smallest version of the same system that can run in production, with real data, real users, real governance, real audit trails, and real failure modes.
Pharma pilots usually scope a POC. The POC succeeds. Then the gap between the POC and the production version becomes visible, and that gap is where the program dies.
Gartner reports that eighty-five percent of AI projects fail due to poor data quality. The reason is structural. A POC runs on a clean, static, hand-picked sample. Production runs on a messy, constantly changing stream of real-world data with all the duplicates, schema drift, missing fields, and edge cases that the POC carefully excluded. The model that worked beautifully on the POC sample collapses on the production stream, and the team rebuilds, and the timeline slips, and the budget cycle ends, and the pilot is now permanently scoped as a "learning exercise."
The companies that escape pilot purgatory scope the smallest meaningful production deployment as the pilot. They build the data plumbing as part of the pilot. They build the audit trail as part of the pilot. They train the operational users as part of the pilot. The pilot finishes already in production. There is no graduation step because there was no separation between pilot and production in the first place.
This is the second reason your pilot is stuck. The shape of what you built was never designed to leave the demo room.
Reason 3: You Built Outside the Operating Model That Has to Absorb It
The third reason is the one that is hardest to fix and the one almost every AI initiative gets wrong.
The pilot was run by a centralized AI team, an external vendor, or a digital transformation function sitting next to the line organization. The line organization, the function that actually has to operate the AI in daily work, was a stakeholder, not an owner. The line organization attended demos. The line organization signed off on requirements. The line organization did not build it, design the workflow around it, or take operational responsibility for it.
When the pilot finished, the AI did not have a home. The central team could not operationalize it because they do not run the function. The line function could not adopt it because they did not design it. The integration into the existing CRM, MLR system, pharmacovigilance platform, or commercial workflow was an afterthought instead of the foundation.
BCG measured this directly. AI success is ten percent algorithms, twenty percent data and technology, and seventy percent people, processes, and cultural transformation. BCG also found that only twenty-five percent of frontline employees receive sufficient leadership guidance on how to use AI effectively. The pilots that fail almost universally underweight the seventy percent and overweight the ten percent.
This is the third reason your pilot is stuck. The architecture sits outside the operating model that needs to absorb it.
The 90-Day Path Out
The path out of pilot purgatory is not "spend more on AI." It is a deliberate ninety-day reset that re-shapes the program around the conditions that actually produce production AI.
I run this as a structured engagement with senior pharma teams. Here is the shape.
Days 0 to 14: Use case re-scoping.
We map every active AI pilot in your organization against three criteria: value chain distance from output to measurable outcome, single-function ownership clarity, and operational data readiness. Most organizations discover that one or two of the current pilots can be re-scoped into production-shape MVPs. The others are quietly archived as "learning exercises" so they stop consuming budget and political capital. You end the two weeks with a written use case priority list, a clear owner per use case, and a defined ninety-day target outcome per use case.
Days 15 to 45: Production-shape build.
The top-priority use case is rebuilt as an MVP, not a POC. The data plumbing is built against your real production data, not a curated sample. The audit trail is built from day one. The human oversight architecture is designed against your existing SOPs and the EU AI Act / FDA-EMA expectations. The line function owns the workflow. The MVP runs on real users by day forty-five.
Days 45 to 90: Live deployment and measurement.
The MVP runs in production for six weeks. We measure baseline-to-pilot performance on the specific business metric the use case was scoped against. We tune the model, the prompts, the governance thresholds, and the human review architecture against real operational signal. The function owner sees their own dashboard. The steering committee sees the value chain from AI output to business outcome, with numbers.
By day ninety, you have one production AI deployment running, with measured outcomes, owned by the function, and with a clear extension path to two or three additional use cases.
That is what gets you out of PowerPoint.
Why This Works
Three reasons.
First, the ninety-day reset attacks the actual root causes of pilot purgatory rather than the surface symptoms. Most AI consulting engagements treat the symptom: build a fancier roadmap, hire a fancier team, deploy a fancier model. The root causes are use case selection, scope shape, and operating model integration. The reset addresses all three in sequence.
Second, the engagement produces operational momentum, not strategic documents. By day ninety, something is running in production with measured outcomes. That single production deployment changes the political dynamics of every subsequent AI conversation inside the company. The board stops asking for strategy updates and starts asking for extension plans.
Third, the engagement is anchored in the pharma operating model, not in a generic enterprise AI playbook. The MLR review path, the pharmacovigilance reporting path, the field force operating cadence, the cross-functional decision cascade, and the regulatory documentation expectations are designed into the deployment from day one. The deployment is built to survive an audit, not just to produce a demo.
What You Get
The ninety-day engagement delivers four things.
A written use case priority assessment specific to your current AI portfolio. Production-shape MVP for the top-priority use case, deployed live with real users by day forty-five. Measured baseline-to-pilot business outcomes by day ninety. A documented extension roadmap to two or three additional use cases, with the operating model implications mapped per use case.
The deliverable that matters most is not on that list. The deliverable that matters most is that by day ninety, you have a production AI deployment in your organization that the board can see, the function can operate, and the next two use cases can be scoped against.
How to Start
The next step is a thirty-minute pilot triage call.
You walk me through your current AI portfolio. The use cases. The vendors. The functions. The status of each pilot. The board's framing. The internal politics. I walk you through the use case re-scoping framework, identify which of your current pilots are the most likely candidates for the ninety-day reset, and tell you which ones I would archive.
The output of the call is a one-page assessment that maps your active pilots against the re-scoping criteria, identifies the highest-leverage starting point for the ninety-day engagement, and shows you what the production-shape MVP would look like for that use case.
No procurement process required for the call. No vendor evaluation. No NDA on the way in.
If you have more than two AI pilots that have been running for over six months and have not graduated to production, this is the call to take this quarter.
Book a 30-minute pilot triage →
The pharma companies that get one production AI deployment running in the next ninety days will be operating at a different pace by the end of 2026. The ones that keep refining the strategy deck will be running the same conversation, with the same slides, in the same room, twelve months from now.
